医学
败血症
重症监护医学
生物标志物
临床判断
临床实习
严重败血症
内科学
感染性休克
物理疗法
医学物理学
生物化学
化学
作者
Zhiwen Yuan,Ruiqiang Zheng,Qihong Chen,Xiaoming Wang
出处
期刊:PubMed
日期:2019-03-01
卷期号:31 (3): 381-384
被引量:1
标识
DOI:10.3760/cma.j.issn.2095-4352.2019.03.026
摘要
Sepsis is the main cause of higher morbidity and mortality in hospitalized patients. Rapid recognition of sepsis as the cause of deterioration is desirable, so effective treatment can be initiated rapidly. More than 170 different biomarkers have been assessed for potential use in sepsis, more for prognosis than for diagnosis. None have sufficient specificity or sensitivity to be routinely employed in clinical practice. Therefore, it is essential for clinicians to seek more specific and sensitive biomarkers to early identify and diagnosis of sepsis patients, and further assess the severity and predict prognosis. Thus, combined biomarkers may be more effective than a single biomarker. This article focused on the current novel biomarkers of sepsis and their potential use at the bedside to guide clinical decision-making.
科研通智能强力驱动
Strongly Powered by AbleSci AI